Limits...
The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.

Al-Arouj M, Hassoun AA, Medlej R, Pathan MF, Shaltout I, Chawla MS, Hristoskova S, Ditommaso S, Kadwa MY - Int. J. Clin. Pract. (2013)

Bottom Line: A higher proportion of SU-treated patients experienced adverse events (AEs) compared with vildagliptin (22.8% vs. 10.2%).In this real-world study of fasting Muslim patients with T2DM, vildagliptin was associated with significantly fewer hypoglycaemic episodes compared with SU therapy.Vildagliptin was well tolerated in this patient population.

View Article: PubMed Central - PubMed

Affiliation: Dasman Diabetes Institute, Kuwait, Kuwait.

Show MeSH

Related in: MedlinePlus

Mean change in HbA1c pre- to post-Ramadan in vildagliptin and SU cohorts. Primary analysis set of patients with both pre- and post-Ramadan HbA1c measurements. *Two sample t-test. Last observation carried forward
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4230330&req=5

fig02: Mean change in HbA1c pre- to post-Ramadan in vildagliptin and SU cohorts. Primary analysis set of patients with both pre- and post-Ramadan HbA1c measurements. *Two sample t-test. Last observation carried forward

Mentions: At the end of the study, the mean change in HbA1c from prefasting baseline levels was –0.24% in the vildagliptin group compared with +0.02% in the SU group (–0.26% between-treatment difference; p < 0.001) (Figure 2). Furthermore, weight changes pre- to post-Ramadan were –0.76 kg with vildagliptin compared with –0.13 kg with SUs, representing a mean between-treatment difference of –0.63 kg (p < 0.001) (Figure 3).


The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.

Al-Arouj M, Hassoun AA, Medlej R, Pathan MF, Shaltout I, Chawla MS, Hristoskova S, Ditommaso S, Kadwa MY - Int. J. Clin. Pract. (2013)

Mean change in HbA1c pre- to post-Ramadan in vildagliptin and SU cohorts. Primary analysis set of patients with both pre- and post-Ramadan HbA1c measurements. *Two sample t-test. Last observation carried forward
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4230330&req=5

fig02: Mean change in HbA1c pre- to post-Ramadan in vildagliptin and SU cohorts. Primary analysis set of patients with both pre- and post-Ramadan HbA1c measurements. *Two sample t-test. Last observation carried forward
Mentions: At the end of the study, the mean change in HbA1c from prefasting baseline levels was –0.24% in the vildagliptin group compared with +0.02% in the SU group (–0.26% between-treatment difference; p < 0.001) (Figure 2). Furthermore, weight changes pre- to post-Ramadan were –0.76 kg with vildagliptin compared with –0.13 kg with SUs, representing a mean between-treatment difference of –0.63 kg (p < 0.001) (Figure 3).

Bottom Line: A higher proportion of SU-treated patients experienced adverse events (AEs) compared with vildagliptin (22.8% vs. 10.2%).In this real-world study of fasting Muslim patients with T2DM, vildagliptin was associated with significantly fewer hypoglycaemic episodes compared with SU therapy.Vildagliptin was well tolerated in this patient population.

View Article: PubMed Central - PubMed

Affiliation: Dasman Diabetes Institute, Kuwait, Kuwait.

Show MeSH
Related in: MedlinePlus